NEKTAR THERAPEUTICS Files 8-K on Financial Condition, Reg FD
Ticker: NKTR · Form: 8-K · Filed: Jan 10, 2024 · CIK: 906709
Complexity: simple
Sentiment: neutral
Topics: financial-condition, regulation-fd, corporate-update
TL;DR
**Nektar Therapeutics just dropped an 8-K on financial results and Reg FD, watch for potential stock movement.**
AI Summary
NEKTAR THERAPEUTICS filed an 8-K on January 10, 2024, to report on its 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure'. This filing indicates that the company is providing an update on its financial performance and other material non-public information, likely in preparation for an upcoming earnings call or investor presentation. For investors, this matters because it signals that new financial information is being disclosed, which could impact the stock price (NKTR) depending on the nature of the results.
Why It Matters
This filing indicates NEKTAR THERAPEUTICS is disclosing new financial information, which could provide critical insights into the company's health and future prospects, directly influencing investor sentiment and stock valuation.
Risk Assessment
Risk Level: medium — The filing itself is administrative, but the underlying financial disclosures could contain positive or negative news, creating market volatility.
Analyst Insight
A smart investor would look for the specific details of the 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' that this 8-K refers to, likely in an accompanying press release or investor presentation, to understand the financial implications before making any trading decisions.
Key Players & Entities
- NEKTAR THERAPEUTICS (company) — the registrant filing the 8-K
- Nasdaq Capital Market (company) — the exchange where NKTR Common Stock is registered
- January 10, 2024 (date) — date of earliest event reported and filing date
- NKTR (company) — trading symbol for Nektar Therapeutics
- 0-24006 (dollar_amount) — Commission File Number
FAQ
What specific items did NEKTAR THERAPEUTICS report on in this 8-K filing?
NEKTAR THERAPEUTICS reported on 'Results of Operations and Financial Condition' and 'Regulation FD Disclosure' as per the Item Information section of the filing.
What is the filing date and the date of the earliest event reported for this 8-K?
Both the filing date and the date of the earliest event reported for this 8-K is January 10, 2024, as stated in the filing.
Where is NEKTAR THERAPEUTICS' Common Stock traded and what is its par value?
NEKTAR THERAPEUTICS' Common Stock, with a par value of $0.0001, is traded on the Nasdaq Capital Market under the trading symbol NKTR, according to the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the business address and phone number of NEKTAR THERAPEUTICS?
The business address for NEKTAR THERAPEUTICS is 455 Mission Bay Boulevard South, San Francisco, California 94158, and their telephone number is (415) 482-5300, as detailed in the filing.
What is NEKTAR THERAPEUTICS' Central Index Key (CIK) and IRS Employer Identification Number?
NEKTAR THERAPEUTICS' Central Index Key (CIK) is 0000906709 and its IRS Employer Identification Number is 94-3134940, as provided in the 'FILER: COMPANY DATA' section and on the cover page of the 8-K.
Filing Stats: 879 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2024-01-10 16:25:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value NKTR Nasdaq Capital Marke
- $329 m — ompany had cash and cash equivalents of $329 million, which should provide a cash runw
Filing Documents
- ea191340-8k_nektar.htm (8-K) — 26KB
- 0001213900-24-002718.txt ( ) — 194KB
- nktr-20240108.xsd (EX-101.SCH) — 3KB
- nktr-20240108_lab.xml (EX-101.LAB) — 33KB
- nktr-20240108_pre.xml (EX-101.PRE) — 22KB
- ea191340-8k_nektar_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEKTAR THERAPEUTICS Date: January 10, 2024 By: /s/ Mark A. Wilson Mark A. Wilson Chief Legal Officer and Secretary 2